PRJNA491728
Feasibility of tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer patients using a droplet PCR amplicon sequencing assay
Precise monitoring and serial profiling of plasma cell free DNA mutations in ESR1, PIK3CA, and TP53. It may have clinical utility as early biomarkers of treatment response in ER+ MBC patients.